Development and validation of sensitive LC-MS/MS assays for quantifi cation of HP- β -CD in human plasma and CSF

Journal of Lipid Research

Volumn 55, Issue 7, 2014, Pages 1537-1548

  Jiang, Hui ^a   Sidhu, Rohini ^a   Fujiwara, Hideji ^a   Meulder, Marc De ^b   De Vries, Ronald ^b   Gong, Yong ^b   Kao, Mark ^b   Porter, Forbes D ^c   Yanjanin, Nicole M ^c   Carillo Carasco, Nuria ^c   Xu, Xin ^d   Ottinger, Elizabeth ^d   Woolery, Myra ^e   Ory, Daniel S ^a   Jiang, Xuntian ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

2 hydroxypropyl cyclodextrin; Cerebrospinal fl uid; In source fragmentation; Liquid chromatography tandem mass spectrometry; Niemann Pick C; Two dimensional liquid chromatography; Ultra performance liquid chromatography

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN;

AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STRUCTURE; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; PLASMA; PRECIPITATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; BLOOD; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PROCEDURES; VALIDATION STUDY;

2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY;

EID: 84903999212     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D050278     Document Type: Article

References (23)

1. Vanier, M. T. 2010. Niemann-Pick disease type C. Orphanet J. Rare Dis. 5: 16.
2. Vanier, M. T., and G. Millat. 2003. Niemann-Pick disease type C. Clin. Genet. 64: 269-281.
3. Liu, B., S. D. Turley, D. K. Burns, A. M. Miller, J. J. Repa, and J. M. Dietschy. 2009. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/-mouse. Proc. Natl. Acad. Sci. USA. 106: 2377-2382.
4. Davidson, C. D., N. F. Ali, M. C. Micsenyi, G. Stephney, S. Renault, K. Dobrenis, D. S. Ory, M. T. Vanier, and S. U. Walkley. 2009. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE. 4: e6951.
5. Liu, B., C. M. Ramirez, A. M. Miller, J. J. Repa, S. D. Turley, and J. M. Dietschy. 2010. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J. Lipid Res. 51: 933-944.
6. Ramirez, C. M., B. Liu, A. M. Taylor, J. J. Repa, D. K. Burns, A. G. Weinberg, S. D. Turley, and J. M. Dietschy. 2010. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr. Res. 68: 309-315.
7. Ward, S., P. O'Donnell, S. Fernandez, and C. H. Vite. 2010. 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease. Pediatr. Res. 68: 52-56.
8. Ottinger, E. A., M. L. Kao, N. Carrillo-Carrasco, N. Yanjanin, R. K. Shankar, M. Janssen, M. Brewster, I. Scott, X. Xu, J. Cradock, et al. 2014. Collaborative development of 2-hydroxypropyl-beta-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr. Top. Med. Chem. 14: 330-339.
9. Szathmary, S. C. 1989. Determination of hydroxypropyl-beta-cyclodextrin in plasma and urine by size-exclusion chromatography with post-column complexation. J. Chromatogr. 487: 99-105.
10. US Department of Health and Human Services Food and Drug Administration. 2001. Guidance for Industry: Bioanalytical Method Validations. Center for Drug Evaluation and Research, Center for Veterinary Medicine. Accessed June 5, 2014, at http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM368107. pdf.
11. Viswanathan, C. T., S. Bansal, B. Booth, A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, and R. Weiner. 2007. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24: 1962-1973.
12. European Medicines Agency (EMA). 2011. Guideline on Bioanalytical Method Validation. Accessed June 5, 2014, at http://www.ema. europa. eu/docs/en-GB/document-library/Scientifi c-guideline/2011/08/WC500109686. pdf.
13. Szente, L., and J. Szejtli. 1999. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 36: 17-28.
14. Hsu, F. F., J. Turk, M. E. Stewart, and D. T. Downing. 2002. Structural studies on ceramides as lithiated adducts by low energy collisional-activated dissociation tandem mass spectrometry with electrospray ionization. J. Am. Soc. Mass Spectrom. 13: 680-695.
15. Farwanah, H., J. Wirtz, T. Kolter, K. Raith, R. H. Neubert, and K. Sandhoff. 2009. Normal phase liquid chromatography coupled to quadrupole time of flight atmospheric pressure chemical ionization mass spectrometry for separation, detection and mass spectrometric profiling of neutral sphingolipids and cholesterol. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 2976-2982.
16. Altman, E., and J. Li. 2010. Characterization of polysaccharides using mass spectrometry for bacterial serotyping. Methods Mol. Biol. 600: 245-257.
17. Prandi, B., L. Farioli, T. Tedeschi, E. A. Pastorello, and S. Sforza. 2012. Simulated gastrointestinal digestion of Pru ar 3 apricot allergen: assessment of allergen resistance and characterization of the peptides by ultra-performance liquid chromatography/electrospray ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 26: 2905-2912.
18. Little, J. L., M. F. Wempe, and C. M. Buchanan. 2006. Liquid chromatography-mass spectrometry/mass spectrometry method development for drug metabolism studies: Examining lipid matrix ionization effects in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 833: 219-230.
19. Li, H., M. J. Rose, J. R. Holder, M. Wright, L. P. Miranda, and C. A. James. 2011. Direct quantitative analysis of a 20 kDa PEGylated human calcitonin gene peptide antagonist in cynomolgus monkey serum using in-source CID and UPLC-MS/MS. J. Am. Soc. Mass Spectrom. 22: 1660-1667.
20. Deng, Y., H. Zhang, J. T. Wu, and T. V. Olah. 2005. Tandem mass spectrometry with online high-fl ow reversed-phase extraction and normal-phase chromatography on silica columns with aqueousorganic mobile phase for quantitation of polar compounds in biological fl uids. Rapid Commun. Mass Spectrom. 19: 2929-2934.
21. Liu, A., J. Tweed, and C. E. Wujcik. 2009. Investigation of an on-line two-dimensional chromatographic approach for peptide analysis in plasma by LC-MS-MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 1873-1881.
22. Johanson, C. E., J. A. Duncan 3rd, P. M. Klinge, T. Brinker, E. G. Stopa, and G. D. Silverberg. 2008. Multiplicity of cerebrospinal fl uid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 5: 10.
23. Yao, J., D. Ho, N. Y. Calingasan, N. H. Pipalia, M. T. Lin, and M. F. Beal. 2012. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J. Exp. Med. 209: 2501-2513.